KDM1A and diffuse large B-cell lymphoma: Thus, the further structure–activity relationship studies of ZY0511 may lead to develop safer and more potent LSD1 inhibitors which inhibits proliferation of DLBCL, and expand the clinical use of LSD1 inhibitors.